WO2014144616A3 - Anti-alpha v beta 5 antibodies and uses thereof - Google Patents

Anti-alpha v beta 5 antibodies and uses thereof Download PDF

Info

Publication number
WO2014144616A3
WO2014144616A3 PCT/US2014/029100 US2014029100W WO2014144616A3 WO 2014144616 A3 WO2014144616 A3 WO 2014144616A3 US 2014029100 W US2014029100 W US 2014029100W WO 2014144616 A3 WO2014144616 A3 WO 2014144616A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
beta
alpha
disclosed
antibody fragments
Prior art date
Application number
PCT/US2014/029100
Other languages
French (fr)
Other versions
WO2014144616A2 (en
Inventor
Shelia M. Violette
Dean Sheppard
Amha Atakilit
Timothy David Jones
Francis Joseph Carr
Anja Sibylle TESSARZ
Original Assignee
Biogen Idec Ma Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., The Regents Of The University Of California filed Critical Biogen Idec Ma Inc.
Publication of WO2014144616A2 publication Critical patent/WO2014144616A2/en
Publication of WO2014144616A3 publication Critical patent/WO2014144616A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Humanized antibodies and antibody fragments that bind to ανβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent avp5-mediated diseases.
PCT/US2014/029100 2013-03-15 2014-03-14 Anti-alpha v beta 5 antibodies and uses thereof WO2014144616A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361798216P 2013-03-15 2013-03-15
US61/798,216 2013-03-15
US201361899001P 2013-11-01 2013-11-01
US61/899,001 2013-11-01

Publications (2)

Publication Number Publication Date
WO2014144616A2 WO2014144616A2 (en) 2014-09-18
WO2014144616A3 true WO2014144616A3 (en) 2014-12-04

Family

ID=50543363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029100 WO2014144616A2 (en) 2013-03-15 2014-03-14 Anti-alpha v beta 5 antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2014144616A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004317A1 (en) * 1998-11-24 2003-01-02 Smithkline Beecham Corporation Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies
WO2005094391A2 (en) * 2004-04-02 2005-10-13 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
WO2007102526A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004317A1 (en) * 1998-11-24 2003-01-02 Smithkline Beecham Corporation Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies
WO2005094391A2 (en) * 2004-04-02 2005-10-13 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
WO2007102526A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONES TIM D ET AL: "Deimmunization of Monoclonal Antibodies", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC, NJ, US, vol. 525, 1 January 2009 (2009-01-01), pages 405 - 423, XP009137530, ISSN: 1064-3745 *
MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285 - 3291, XP002649029, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2014144616A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
WO2014151680A8 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2020004503A (en) Humanized or chimeric cd3 antibodies.
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2022011002A (en) Humanized or chimeric cd3 antibodies.
NZ738008A (en) Tigit-binding agents and uses thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
MX2017012802A (en) Anti-sortilin antibodies and methods of use thereof.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
EA201790342A1 (en) ANTIBODIES TO TREM2 AND METHODS OF THEIR APPLICATION
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
EP3411069A4 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
EP3181587A4 (en) Anti-human il-17 monoclonal antibody and use thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EP3095796A4 (en) Anti-human probdnf monoclonal antibody, and uses thereof in pains
IL255314A0 (en) Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EP3500293A4 (en) Methods of treating crohn's disease with an anti-nkg2d antibody
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
WO2017019957A3 (en) Binding proteins and methods of use thereof
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718868

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718868

Country of ref document: EP

Kind code of ref document: A2